Fludrocortisone
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Fludrocortisone
- Molecular weight
- 380.46
- Structure (SMILES)
- C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
- alflorone
- Alflorone
- astonin h
- Astonin-h
- fludrocortisone
- Fludrocortisone
- FLUDROCORTISONE [HSDB]
- fludrocortisone [INN]
- FLUDROCORTISONE [MI]
- FLUDROCORTISONE [VANDF]
- Fludrocortisone [WHO-DD]
- fludrocortisone 50 mcg daily
- Fludrocortisone 50 mcg daily
- fludrocortisone hsdb
- fludrocortisone inn
- fludrocortisone mi
- fludrocortisone vandf
- fludrocortisone who dd
- nsc 11318
- NSC-11318
- ATC classification codes
- H02AA02
Sources for recorded values
- CAS registry numbers
- 127-31-1
- ChEMBL ID
- CHEMBL1201388
- InChIKey
- AAXVEMMRQDVLJB-BULBTXNYSA-N
- PubChem compound IDs
- 31378
- RxNorm IDs (RxCUI)
- 4452
- FDA ingredient codes (UNII)
- U0476M545B
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fludrocortisone
- Type
- Synthetic organic
- Drug name stem
- -cort-
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Median affinity
- 9.92
- Affinity units
- pIC50
- Primary target
- Yes
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- HP_0012076
- Condition identifier
- HP_0100806
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002050
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005147
- Condition identifier
- MONDO_0011972
- Highest recorded phase
- 2
- Event
- accelerated hypertension
- Reports
- 3
- Reporting signal score
- 14.002
- Event
- acute psychosis
- Reports
- 10
- Reporting signal score
- 40.3405
- Event
- adrenal insufficiency
- Reports
- 6
- Reporting signal score
- 13.7243
- Event
- adrenocortical insufficiency acute
- Reports
- 4
- Reporting signal score
- 15.2333
- Event
- androgens abnormal
- Reports
- 1
- Reporting signal score
- 6.17121
- Event
- autonomic failure syndrome
- Reports
- 2
- Reporting signal score
- 13.3418
- Event
- blood pressure increased
- Reports
- 11
- Reporting signal score
- 10.6076
- Event
- cerebral hypoperfusion
- Reports
- 2
- Reporting signal score
- 8.81654
- Event
- cerebrovascular accident
- Reports
- 33
- Reporting signal score
- 57.538
- Event
- cognitive disorder
- Reports
- 11
- Reporting signal score
- 19.9085
- Event
- confusional state
- Reports
- 16
- Reporting signal score
- 15.8753
- Event
- cushingoid
- Reports
- 3
- Reporting signal score
- 8.09522
- Event
- dermatitis bullous
- Reports
- 7
- Reporting signal score
- 18.1988
- Event
- disorientation
- Reports
- 14
- Reporting signal score
- 28.2715
- Event
- dizziness
- Reports
- 19
- Reporting signal score
- 6.87739
- Event
- dizziness postural
- Reports
- 4
- Reporting signal score
- 9.93032
- Event
- dyskinesia
- Reports
- 10
- Reporting signal score
- 18.8269
- Event
- dystonia
- Reports
- 12
- Reporting signal score
- 31.7602
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 4
- Reporting signal score
- 10.2273
- Event
- eosinophilic oesophagitis
- Reports
- 7
- Reporting signal score
- 37.2738
- Event
- executive dysfunction
- Reports
- 3
- Reporting signal score
- 14.7695
- Event
- fall
- Reports
- 24
- Reporting signal score
- 18.5947
- Event
- foaming at mouth
- Reports
- 3
- Reporting signal score
- 11.1043
- Event
- gastritis
- Reports
- 5
- Reporting signal score
- 7.21539
- Event
- glomerulonephritis membranous
- Reports
- 5
- Reporting signal score
- 20.5263
And 21 more, listed on the interactive page.
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 94.83
- Calculated partition coefficient (ALogP)
- 1.87
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 27
- Molecular formula
- C21H29FO5
- Monoisotopic mass
- 380.19990218
- Natural product
- No
- Recorded assays
- 1,193
- Active assays
- 54
- Confirmatory
- Other
- Summary
- Anti-Inflammatory Agents
Related records
Trials (36)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
- A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects
- A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
- Activated Protein C and Corticosteroids for Human Septic Shock
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
- Adjunctive Fludrocortisone in Septic Shock
- Androgen Reduction in Congenital Adrenal Hyperplasia
- Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
- Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression
- Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock
- Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension
- Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
- Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
- FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
- Fludrocortisone and Information Processing in Healthy Volunteers
- Fludrocortisone for Sudden Hearing Loss
- Fludrocortisone in Healthy Volunteers (AFLUCO4)
In development for (2)
- Acute kidney injury Phase 3
- Ovarian hyperstimulation syndrome Phase 2
Other linked conditions (4)
- Borderline personality disorder
- Depressive disorder
- Major depressive disorder
- Type 1 diabetes mellitus